Weight Loss
Resources
Basic InformationMore InformationLatest News
FDA Requests Market Withdrawal of Diet Drug Belviq Due to Cancer RiskFor Teens, Weight-Loss Surgery May Not Bring Emotional GainsAHA News: A Sweet Super Bowl Treat That Won't Sack Your HealthWeight-Loss Surgery Brings Surprise Bonus: Breathing EasierAHA News: Processed vs. Ultra-Processed Food, and Why It Matters to Your HealthWhich Obesity Surgery Is Right for You?Could Your Morning Coffee Be a Weight-Loss Tool?What Matters More for Obesity Risk, Genes or Lifestyle?Calories Per Serving or the Whole Package? Many Food Labels Now Tell BothWeight-Loss Surgery Might Also Lower Skin Cancer RiskNew Year's Resolutions Didn't Stick? Try a Monday ResetA Breakfast Fit for Making Your New Year's ResolutionsToast a Healthy New Year With These Holiday Cocktail RecipesBetter Choices for a Fast, Healthy LunchHow You Can Be Overfat Without Being Overweight'Intermittent Fasting' Diet Could Boost Your HealthThe Financial Reward of Slimming DownDelicious Holiday Desserts With Fewer CaloriesAHA News: How to Enjoy the Flavors of the Season Without Derailing HealthWeight-Loss Surgery a Boon for the HeartHealth Tip: Strengthen Self-ControlHealth Tip: Thanksgiving and Your Heart HealthAHA News: Eating Mindfully Through the Holidays – and All YearHealth Tip: Measuring Weight Accurately at HomeMore Americans Trying to Lose Weight, But Few SucceedingThe On-Again, Off-Again Weight-Loss DietWeight-Loss Surgery: Better Health, But No Cost SavingsStaying Slim After Weight-Loss Surgery Could Cut Cancer Risk in HalfHow to Head Off Holiday Weight GainAnother Weight-Loss Surgery Benefit: Lower Breast Cancer RiskWeight-Loss Surgery Protects Heart Patients From Future TroubleWhen You Eat May Matter More Than What You Eat: StudyDeep Sleep May 'Rinse' Day's Toxins From BrainToo Much Salt Might Make You Gain WeightExperts Support Weight-Loss Surgery for Very Obese KidsTry These Homemade Chocolate Treats for HalloweenWhy Maintaining a Healthy Weight Is Important in AdulthoodMoms' Weight-Loss Surgery Tied to Lower Risk of Birth DefectsAre You Eating More Calories Than You Think?You've Lost the Weight -- Now Keep It Off to Keep Diabetes at BayWhy Maintaining Weight Loss Demands More Than WillpowerHow to Rebalance Your Carb IntakeSeasonal Drinks With a Lighter TouchLighten Up Your Favorite Mac 'N' CheeseFoods That Will Make You Feel Full FasterCan You Still Be Healthy If You're Overweight?What's the Right Balance of Fats and Carbs?How Your Genes Affect the Number on Your ScaleSoups Are the New Smoothies5 Ways to Cut the Fat From Your Diet
LinksSelf-Help Groups
Related Topics

Wellness and Personal Development
Men's Health
Women's Health

FDA Requests Market Withdrawal of Diet Drug Belviq Due to Cancer Risk

HealthDay News
by -- E.J. Mundell
Updated: Feb 14th 2020

new article illustration

THURSDAY, Feb. 13, 2020 (HealthDay News) -- A clinical trial of the weight-loss drug Belviq (lorcaserin) shows an association with an increased risk of cancer, and the U.S. Food and Drug Administration is requesting that its maker withdraw the drug from the U.S. market.

Eisai Inc. has already "submitted a request to voluntarily withdraw the drug," Dr. Janet Woodcock, who directs the FDA's Center for Drug Evaluation and Research, noted in a statement issued Thursday.

Now, "we're taking steps to notify the public," she said, adding that "our review of the full clinical trial results shows that the potential risk of cancer associated with the drug outweighs the benefit of treatment."

Woodcock said the FDA is advising that "patients should stop using the medication Belviq and Belviq XR [lorcaserin] and talk to their health care professionals about other treatment options for weight loss. Health care professionals should stop prescribing and dispensing Belviq and Belviq XR."

The agency first announced that Belviq might have links to cancer in a communication issued Jan 15.

At the time, the FDA said "we cannot conclude that lorcaserin contributes to the cancer risk," but "wanted to make the public aware of this potential risk. We are continuing to evaluate the clinical trial results and will communicate our final conclusions and recommendations when we have completed our review."

That review appears to have led to calls for the voluntary withdrawal of the medication.

Belviq increases feelings of fullness so that people eat less. It's available as a tablet (Belviq) and an extended-release tablet (Belviq XR).

According to the FDA, Belviq was first approved in 2012 as an add-on therapy to help aid weight loss, along with diet and exercise, in people who were obese or overweight.

Contingent on approval, the FDA ordered a randomized, placebo-controlled trial be conducted involving 12,000 people tracked for more than five years.

The trial wrapped up in June 2018, and the data showed that while 7.1% of those taking a "dummy" placebo developed cancer, that number rose to 7.7% among those taking Belviq.

"A range of cancer types was reported," the FDA said. "Several different types of cancers occurred more frequently among patients treated with Belviq, including pancreatic, colorectal and lung cancer. During the trial, one additional cancer per 470 patients treated with the medication for one year was observed."

People who have already taken Belviq should stop taking it, but "the FDA is not recommending special screening for patients who have taken Belviq," Woodcock said.

More information

There's more on maintaining a healthy weight at the American Heart Association.




328 W. Claiborne St.
P.O. Box 964
Monroeville,
Alabama 36460
Tel: (251)575-4203
Fax:(251)575-9459


powered by centersite dot net